Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 EUR | -0.43% | +10.05% | +2.68% |
29/04 | Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
19/04 | Theranexus: share price rises following promising trial results | CF |
Business Summary
Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.
Number of employees: 19
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 19/13/19 | |
Founder | - | 19/13/19 | |
Director of Finance/CFO | - | 01/17/01 | |
Marie Sebille
CTO | Chief Tech/Sci/R&D Officer | - | 19/21/19 |
Human Resources Officer | - | 01/18/01 | |
Julien Veys
PRN | Corporate Officer/Principal | - | 01/16/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jérôme Martinez
BRD | Director/Board Member | 63 | 13/18/13 |
Director/Board Member | 50 | 26/17/26 | |
Founder | - | 19/13/19 | |
Chief Executive Officer | - | 19/13/19 | |
Director/Board Member | 51 | - | |
Eric Doulat
BRD | Director/Board Member | - | 01/20/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,346,213 | 4,220,699 ( 78.95 %) | 0 | 78.95 % |
Company contact information
Theranexus SA
Pépinière Laennec 60, avenue Rockefeller
69008, Lyon
+33 1 88 89 70 31
http://www.theranexus.comSector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.68% | 9.53M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+2.13% | 22.25B | |
-14.77% | 21.68B | |
-8.79% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- ALTHX Stock
- Company Theranexus